Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists

Rama Kondru, Jun Zhang, Changhua Ji, Tara Mirzadegan, David Rotstein, Surya Sankuratri and Marianna Dioszegi
Molecular Pharmacology March 2008, 73 (3) 789-800; DOI: https://doi.org/10.1124/mol.107.042101
Rama Kondru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changhua Ji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara Mirzadegan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Rotstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surya Sankuratri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianna Dioszegi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In addition to being an important receptor in leukocyte activation and mobilization, CCR5 is the essential coreceptor for human immunodeficiency virus (HIV). A large number of small-molecule CCR5 antagonists have been reported that show potent activities in blocking chemokine function and HIV entry. To facilitate the design and development of next generation CCR5 antagonists, docking models for major classes of CCR5 antagonists were created by using site-directed mutagenesis and CCR5 homology modeling. Five clinical candidates: maraviroc, vicriviroc, aplaviroc, TAK-779, and TAK-220 were used to establish the nature of the binding pocket in CCR5. Although the five antagonists are very different in structure, shape, and electrostatic potential, they were able to fit in the same binding pocket formed by the transmembrane (TM) domains of CCR5. It is noteworthy that each antagonist displayed a unique interaction profile with amino acids lining the pocket. Except for TAK-779, all antagonists showed strong interaction with Glu283 in TM 7 via their central basic nitrogen. The fully mapped binding pocket of CCR5 is being used for structure-based design and lead optimization of novel anti-HIV CCR5 inhibitors with improved potency and better resistance profile.

Footnotes

  • ABBREVIATIONS: HIV, human immunodeficiency virus; VVC, vicriviroc, (4,6-dimethyl-pyrimidin-5-yl)-(4-{(S)-4-[(R)-2 methoxy-1-(4-trifluoromethylphenyl)-ethyl]-3-methyl-piperazin-1-yl}-4-methyl-piperidin-1-yl)-methanone; APL, aplaviroc, 4-[4-(1-butyl-3-cyclohexylmethyl-2,5-dioxo-1,4,9 triazaspiro[5.5]undec-9-ylmethyl)-phenoxy]-benzoic acid; MVC, maraviroc, 4,4-difluoro-cyclohexanecarboxylic acid {(S)-3 [(1S,3S,5R)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide; TAK-779, dimethyl-(tetrahydro-pyran-4-yl)-{4-[(3-p-tolyl-8,9-dihydro 7H-benzocycloheptene-6-carbonyl)-amino]-benzyl}-ammonium; TAK-220, 1-Acetyl-piperidine-4-carboxylic acid {3-[4-(4-carbamoyl-benzyl)-piperidin-1-yl]-propyl}-(3-chloro-4-methyl-phenyl)-amide; SCH-C, SCH-351125, (4-{(4-bromo-phenyl)-[(Z)-ethoxyimino]-methyl}-4′-methyl-[1,4′]bipiperidinyl-1′-yl)-(2,4-dimethyl-1-oxy-pyridin-3-yl)-methanone; TM, transmembrane; ECL, extracellular loop; FACS, fluorescence-activated cell sorting; RANTES, regulated upon activation, normal T cell expressed and secreted; MIP-1α, macrophage inflammatory protein-1α; CHO, Chinese hamster ovary; GPCR, G protein-coupled receptor.

    • Received September 25, 2007.
    • Accepted December 20, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 73 (3)
Molecular Pharmacology
Vol. 73, Issue 3
1 Mar 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists

Rama Kondru, Jun Zhang, Changhua Ji, Tara Mirzadegan, David Rotstein, Surya Sankuratri and Marianna Dioszegi
Molecular Pharmacology March 1, 2008, 73 (3) 789-800; DOI: https://doi.org/10.1124/mol.107.042101

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists

Rama Kondru, Jun Zhang, Changhua Ji, Tara Mirzadegan, David Rotstein, Surya Sankuratri and Marianna Dioszegi
Molecular Pharmacology March 1, 2008, 73 (3) 789-800; DOI: https://doi.org/10.1124/mol.107.042101
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics